Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Novo Nordisk A/S. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$811.73 +6.30 (+0.78%)
Closing price 03:59 PM Eastern
Extended Trading
$811.50 -0.23 (-0.03%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $799, reflecting a strong market position and investor confidence in the company's future growth.
  • Eli Lilly and Co reported a significant revenue increase of over 45% compared to the same quarter last year, indicating robust business performance and demand for its products.
  • The company has a high return on equity of over 85%, suggesting effective management and a strong ability to generate profits from shareholders' investments.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, reporting an EPS of $3.34 compared to the consensus estimate of $4.64, which may raise concerns about future profitability.
  • Despite strong revenue growth, the high P/E ratio of around 65 suggests that the stock may be overvalued, which could lead to price corrections.
  • Analysts have mixed ratings, with some downgrading their outlook, indicating uncertainty in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$763.33 billion
P/E Ratio
66.05
Consensus Rating
Moderate Buy
Consensus Price Target
$1,012.56 (+24.7% Upside)
Volume
2.98 million shares
Average Volume
2.81 million shares
Today's Range
$802.37
$815.19
50-Day Range
$713.99
$818.56
52-Week Range
$677.09
$972.53
Dividend Yield
0.74%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$168.29 -1.27 (-0.75%)
Closing price 03:59 PM Eastern
Extended Trading
$168.38 +0.09 (+0.06%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $156.91, which may present a buying opportunity for investors looking for value in a stable company.
  • Johnson & Johnson recently reported strong quarterly earnings, with earnings per share (EPS) of $2.77, exceeding expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $376 billion, reflecting its significant presence and stability in the healthcare sector.

Cons of Johnson & Johnson

  • Despite its strong performance, the stock has a relatively high price-to-earnings (P/E) ratio of 17.40, which may suggest that it is overvalued compared to its earnings.
  • Analysts have mixed ratings on the stock, with several recent downgrades, indicating uncertainty about its future performance.
  • The company has a beta of 0.41, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$407.97 billion
P/E Ratio
18.00
Consensus Rating
Moderate Buy
Consensus Price Target
$174.50 (+3.7% Upside)
Volume
6.20 million shares
Average Volume
8.38 million shares
Today's Range
$167.44
$169.88
50-Day Range
$149.81
$169.62
52-Week Range
$140.68
$169.99
Dividend Yield
3.07%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$190.22 -0.61 (-0.32%)
Closing price 03:59 PM Eastern
Extended Trading
$190.80 +0.58 (+0.30%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $190, which is significantly lower than its twelve-month high, suggesting potential for price appreciation.
  • AbbVie recently reported strong quarterly earnings, with earnings per share of $2.46, exceeding expectations and indicating robust financial health.
  • The company has a solid revenue growth of 8.4% year-over-year, reflecting its ability to expand its market presence and product offerings.

Cons of AbbVie

  • AbbVie has a high dividend payout ratio of 279.15%, which may raise concerns about the sustainability of its dividend payments in the long term.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 81.31, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite positive earnings, the company's net margin of 7.31% is relatively low, indicating potential challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$337.08 billion
P/E Ratio
80.94
Consensus Rating
Moderate Buy
Consensus Price Target
$211.29 (+11.1% Upside)
Volume
3.79 million shares
Average Volume
6.46 million shares
Today's Range
$188.53
$191.40
50-Day Range
$181.74
$194.96
52-Week Range
$163.81
$218.66
Dividend Yield
3.44%
Novo Nordisk A/S stock logo

4. Novo Nordisk A/S NYSE:NVO

$71.67 +0.94 (+1.33%)
Closing price 03:59 PM Eastern
Extended Trading
$71.69 +0.02 (+0.03%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $70, reflecting a stable market position and potential for growth.
  • Recent quarterly earnings showed a strong performance with earnings per share meeting consensus estimates, indicating consistent profitability.
  • The company has a high net margin, suggesting efficient operations and strong profitability relative to its revenue.

Cons of Novo Nordisk A/S

  • The stock has experienced fluctuations, with a 52-week high significantly higher than the current price, which may indicate volatility.
  • Recent selling by some institutional investors could signal a lack of confidence or a strategic shift away from the stock.
  • The company's debt-to-equity ratio suggests a moderate level of debt, which could be a concern for risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$315.81 billion
P/E Ratio
21.20
Consensus Rating
Hold
Consensus Price Target
$112.00 (+56.3% Upside)
Volume
7.35 million shares
Average Volume
7.14 million shares
Today's Range
$70.57
$71.80
50-Day Range
$64.32
$81.07
52-Week Range
$57.00
$139.74
Dividend Yield
2.32%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$280.69 +2.11 (+0.76%)
Closing price 03:59 PM Eastern
Extended Trading
$281.65 +0.97 (+0.34%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $299.70, which may present a buying opportunity for investors looking for value.
  • UnitedHealth Group has a strong annualized dividend of $8.84, providing a yield of 2.94%, which can be attractive for income-focused investors.
  • Analysts have a consensus rating of "Moderate Buy" with an average price target of $415.00, indicating potential upside from the current price.

Cons of UnitedHealth Group

  • Recent downgrades from several analysts, including a reduction in price targets, may indicate a lack of confidence in short-term performance.
  • The stock has experienced volatility, with a 12-month high of $630.73 and a low of $248.88, suggesting potential instability.
  • UnitedHealth Group's debt-to-equity ratio of 0.71 indicates a moderate level of debt, which could pose risks if market conditions worsen.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$252.71 billion
P/E Ratio
11.75
Consensus Rating
Moderate Buy
Consensus Price Target
$392.29 (+39.8% Upside)
Volume
16.45 million shares
Average Volume
12.35 million shares
Today's Range
$279.94
$286.14
50-Day Range
$278.52
$325.83
52-Week Range
$248.88
$630.73
Dividend Yield
3.17%
Novartis stock logo

6. Novartis NYSE:NVS

$117.62 +0.16 (+0.13%)
Closing price 03:59 PM Eastern
Extended Trading
$117.16 -0.46 (-0.39%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $116, which is near its 52-week high of $124.83, indicating strong market performance and potential for further growth.
  • Novartis AG reported a significant increase in quarterly revenue, with a year-over-year growth of approximately 12.3%, showcasing its strong market position and demand for its healthcare products.
  • The company has a robust return on equity of over 41%, reflecting effective management and profitability, which can be attractive to investors looking for solid returns.

Cons of Novartis

  • The company has a current ratio of 0.82, which is below the ideal benchmark of 1, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
  • Despite strong revenue growth, the company’s quick ratio of 0.62 indicates that it may struggle to cover its immediate liabilities without selling inventory, which could be a concern for investors.
  • Novartis AG has a debt-to-equity ratio of 0.53, which, while manageable, indicates that the company is somewhat reliant on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$248.13 billion
P/E Ratio
17.12
Consensus Rating
Hold
Consensus Price Target
$123.67 (+5.1% Upside)
Volume
2.46 million shares
Average Volume
1.86 million shares
Today's Range
$116.25
$117.71
50-Day Range
$109.57
$123.83
52-Week Range
$96.06
$124.83
Dividend Yield
2.21%
AstraZeneca stock logo

7. AstraZeneca NASDAQ:AZN

$72.66 -1.02 (-1.38%)
Closing price 04:00 PM Eastern
Extended Trading
$73.57 +0.91 (+1.25%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $68.79, which may present a buying opportunity for investors looking for value.
  • AstraZeneca reported earnings per share (EPS) of $1.24 for the latest quarter, exceeding expectations, indicating strong financial performance.
  • The company has shown a revenue increase of 7.2% compared to the same quarter last year, suggesting growth potential.

Cons of AstraZeneca

  • The company’s revenue for the latest quarter was slightly below consensus estimates, which may raise concerns about future performance.
  • AstraZeneca has a current ratio of 0.90, indicating potential liquidity issues, as it suggests the company may not have enough short-term assets to cover its short-term liabilities.
  • The stock has experienced fluctuations, with a one-year low of $61.24, which may indicate volatility and risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$228.51 billion
P/E Ratio
29.18
Consensus Rating
Moderate Buy
Consensus Price Target
$89.00 (+22.5% Upside)
Volume
6.20 million shares
Average Volume
3.85 million shares
Today's Range
$72.27
$72.90
50-Day Range
$68.72
$75.00
52-Week Range
$61.24
$87.68
Dividend Yield
2.80%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$126.53 +0.89 (+0.71%)
Closing price 03:59 PM Eastern
Extended Trading
$126.23 -0.30 (-0.24%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The company recently reported earnings per share of $1.26, meeting consensus estimates, which indicates strong financial performance and stability.
  • Abbott Laboratories achieved a revenue of $11.14 billion for the quarter, surpassing expectations, reflecting robust demand for its healthcare products.
  • The current stock price is around $125.80, which is within a reasonable range compared to its 1-year high of $141.23, suggesting potential for growth.

Cons of Abbott Laboratories

  • Despite strong earnings, the stock has seen fluctuations, with a 1-year low of $99.92, indicating potential volatility that could concern risk-averse investors.
  • The company's dividend payout ratio is 29.57%, which, while sustainable, may limit the potential for future dividend increases if earnings do not grow significantly.
  • Recent analyst ratings show mixed sentiments, with five analysts rating the stock as a hold, suggesting some uncertainty about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.59 billion
P/E Ratio
15.86
Consensus Rating
Moderate Buy
Consensus Price Target
$144.47 (+14.2% Upside)
Volume
4.74 million shares
Average Volume
7.57 million shares
Today's Range
$125.45
$126.73
50-Day Range
$120.76
$138.13
52-Week Range
$99.92
$141.23
Dividend Yield
1.88%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$84.82 +0.71 (+0.84%)
Closing price 03:59 PM Eastern
Extended Trading
$84.92 +0.11 (+0.12%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $83.80, which reflects a stable market position and potential for growth.
  • Merck recently reported earnings per share that exceeded analyst expectations, indicating strong financial performance and effective management.
  • The company has a solid dividend yield of approximately 3.87%, providing a reliable income stream for investors.

Cons of Merck & Co., Inc.

  • The company's revenue has shown a slight decline year-over-year, which may raise concerns about future growth prospects.
  • Some analysts have downgraded their ratings, reflecting caution regarding Merck's market performance and potential challenges ahead.
  • Merck's stock has experienced volatility, with a 52-week high of $129.03 and a low of $73.31, indicating potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$211.20 billion
P/E Ratio
12.35
Consensus Rating
Hold
Consensus Price Target
$108.69 (+28.1% Upside)
Volume
10.06 million shares
Average Volume
14.32 million shares
Today's Range
$83.84
$85.22
50-Day Range
$76.08
$84.22
52-Week Range
$73.31
$128.73
Dividend Yield
3.85%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$478.60 +3.58 (+0.75%)
Closing price 03:59 PM Eastern
Extended Trading
$474.00 -4.61 (-0.96%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The stock is currently rated as a "Moderate Buy" by analysts, indicating positive sentiment and potential for growth.
  • Recent analyst upgrades have set price targets around $590 to $637, suggesting significant upside potential from the current stock price.
  • Institutional investors and hedge funds own a substantial 89.23% of the stock, reflecting strong confidence in the company's future performance.

Cons of Thermo Fisher Scientific

  • Recent price target reductions by analysts indicate some uncertainty about the company's near-term performance.
  • Insider ownership is relatively low at 0.33%, which may suggest a lack of confidence from executives in the company's future prospects.
  • Market volatility and economic conditions could impact the demand for Thermo Fisher Scientific Inc.'s products and services.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$179.32 billion
P/E Ratio
27.68
Consensus Rating
Moderate Buy
Consensus Price Target
$593.00 (+23.9% Upside)
Volume
4.19 million shares
Average Volume
3.11 million shares
Today's Range
$474.41
$483.60
50-Day Range
$390.17
$475.16
52-Week Range
$385.46
$627.88
Dividend Yield
0.36%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$495.86 +7.25 (+1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$494.90 -0.96 (-0.19%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $501.95, which may present a buying opportunity for investors looking for growth in the medical equipment sector.
  • Intuitive Surgical, Inc. reported a significant year-over-year revenue increase of 21.4%, indicating strong demand for its products and potential for continued growth.
  • The company has a robust net margin of 28.51%, suggesting efficient operations and the ability to generate profit from its revenues.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings (P/E) ratio of 70.01, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been observed, with a total of 4,998 shares sold recently, which could indicate a lack of confidence from those closest to the company.
  • The stock has experienced volatility, with a beta of 1.64, meaning it is more volatile than the market, which could pose risks for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$175.16 billion
P/E Ratio
69.16
Consensus Rating
Moderate Buy
Consensus Price Target
$592.05 (+19.4% Upside)
Volume
1.87 million shares
Average Volume
1.84 million shares
Today's Range
$490.76
$497.50
50-Day Range
$488.61
$563.60
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$306.58 -1.97 (-0.64%)
Closing price 04:00 PM Eastern
Extended Trading
$306.58 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $309, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Amgen Inc. reported a significant earnings per share (EPS) of $4.90, surpassing analysts' expectations, which suggests strong financial performance and potential for future growth.
  • The company has shown a year-over-year revenue increase of 9.4%, indicating robust business growth and effective management strategies.

Cons of Amgen

  • The company has a high debt-to-equity ratio of 8.70, indicating that it relies heavily on debt financing, which could pose risks in times of economic downturns.
  • Insider selling activity has been noted, with a senior vice president recently selling shares, which may raise concerns about the company's future outlook from those within the organization.
  • Despite recent revenue growth, the competitive landscape in the biotechnology sector is intense, and Amgen Inc. may face challenges in maintaining its market position.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$165.91 billion
P/E Ratio
27.97
Consensus Rating
Hold
Consensus Price Target
$307.27 (+0.2% Upside)
Volume
1.45 million shares
Average Volume
1.94 million shares
Today's Range
$304.45
$309.03
50-Day Range
$271.34
$309.22
52-Week Range
$253.30
$340.89
Dividend Yield
3.09%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$106.07 -0.14 (-0.13%)
Closing price 03:59 PM Eastern
Extended Trading
$106.13 +0.07 (+0.06%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Recent price target increases by analysts, including a raise to $135.00 by UBS Group, suggest strong growth potential, indicating confidence in the company's future performance.
  • The current stock price is around $105, which is significantly below the average target price of $117.50, indicating potential for price appreciation.
  • Boston Scientific Co. has received multiple "buy" ratings from various brokerages, reflecting a consensus among analysts that the stock is a good investment opportunity.

Cons of Boston Scientific

  • The stock has experienced fluctuations, with a recent trading volume lower than its average, which may indicate reduced investor interest or confidence.
  • Despite positive ratings, the price-to-earnings ratio is relatively high, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Market volatility can impact stock performance, and the current economic climate may pose risks to the healthcare sector, including Boston Scientific Co.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.13 billion
P/E Ratio
63.14
Consensus Rating
Buy
Consensus Price Target
$117.50 (+10.8% Upside)
Volume
5.88 million shares
Average Volume
7.85 million shares
Today's Range
$105.94
$107.25
50-Day Range
$98.43
$107.51
52-Week Range
$71.88
$108.94
Dividend Yield
N/A
Stryker stock logo

14. Stryker NYSE:SYK

$403.34 +6.68 (+1.68%)
Closing price 03:59 PM Eastern
Extended Trading
$403.00 -0.34 (-0.08%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $400, reflecting strong market interest and potential for growth.
  • Recent earnings reports show that Stryker Co. exceeded revenue expectations, indicating robust business performance.
  • Analysts have a favorable outlook, with a significant number rating the stock as a "buy," suggesting confidence in future performance.

Cons of Stryker

  • The stock has a high price-to-earnings (P/E) ratio, which may indicate that it is overvalued compared to its earnings.
  • Market volatility could impact stock performance, especially in the healthcare sector, which can be sensitive to regulatory changes.
  • Despite strong earnings, the company faces competition from other medical technology firms, which could affect market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.40 billion
P/E Ratio
54.51
Consensus Rating
Moderate Buy
Consensus Price Target
$428.55 (+6.3% Upside)
Volume
963,567 shares
Average Volume
1.16 million shares
Today's Range
$396.40
$403.79
50-Day Range
$373.22
$400.78
52-Week Range
$314.93
$406.19
Dividend Yield
0.85%
Danaher stock logo

15. Danaher NYSE:DHR

$205.60 +2.79 (+1.38%)
Closing price 03:59 PM Eastern
Extended Trading
$205.60 0.00 (0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $203, reflecting a recent increase of 2.6%, which may indicate positive market sentiment.
  • Danaher Co. has received multiple "buy" ratings from analysts, suggesting strong confidence in its future performance.
  • The company has a solid market capitalization of approximately $145 billion, indicating a strong position in the market.

Cons of Danaher

  • Recent adjustments in earnings estimates by analysts, such as a reduction from $1.88 to $1.72 for Q3 2025, may signal potential challenges ahead.
  • Some analysts have lowered their price targets for Danaher Co., indicating a cautious outlook on its stock performance.
  • The stock has experienced significant fluctuations, with a 12-month high of $281.70 and a low of $171.00, suggesting volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.22 billion
P/E Ratio
43.74
Consensus Rating
Moderate Buy
Consensus Price Target
$247.61 (+20.4% Upside)
Volume
5.36 million shares
Average Volume
3.97 million shares
Today's Range
$202.66
$206.39
50-Day Range
$184.79
$205.55
52-Week Range
$171.00
$281.70
Dividend Yield
0.63%
Pfizer stock logo

16. Pfizer NYSE:PFE

$24.78 -0.57 (-2.23%)
Closing price 03:59 PM Eastern
Extended Trading
$24.80 +0.02 (+0.08%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $25.32, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. recently reported earnings per share of $0.92, exceeding analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has a solid market capitalization of approximately $144 billion, reflecting its stability and established presence in the industry.

Cons of Pfizer

  • The company's revenue has decreased by 7.8% year-over-year, which may raise concerns about its growth trajectory and market competitiveness.
  • Pfizer Inc. has a relatively high dividend payout ratio of 124.64%, indicating that it is paying out more in dividends than it is earning, which could be unsustainable in the long run.
  • Recent target price reductions by several analysts, including BMO Capital Markets lowering it from $36.00 to $30.00, may signal a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$144.12 billion
P/E Ratio
17.96
Consensus Rating
Hold
Consensus Price Target
$28.55 (+15.2% Upside)
Volume
35.63 million shares
Average Volume
38.21 million shares
Today's Range
$24.62
$24.97
50-Day Range
$22.83
$25.77
52-Week Range
$20.92
$31.54
Dividend Yield
6.78%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$116.20 +3.00 (+2.65%)
Closing price 04:00 PM Eastern
Extended Trading
$115.70 -0.51 (-0.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $113.56, reflecting a positive trend in the market and potential for growth.
  • Gilead Sciences, Inc. has a strong portfolio of products, including the latest treatments for HIV/AIDS and COVID-19, which address significant unmet medical needs.
  • The company reported earnings per share of $1.81, exceeding analysts' expectations, indicating strong financial performance and potential for future profitability.

Cons of Gilead Sciences

  • Insider sales totaled 72,000 shares recently, which could signal a lack of confidence among executives regarding the stock's future performance.
  • The company has a debt-to-equity ratio of 1.16, indicating a relatively high level of debt compared to equity, which could pose risks in economic downturns.
  • Gilead Sciences, Inc. has faced challenges in meeting revenue expectations, with recent quarterly revenue falling short of consensus estimates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.81 billion
P/E Ratio
24.46
Consensus Rating
Moderate Buy
Consensus Price Target
$112.36 (-3.3% Downside)
Volume
7.68 million shares
Average Volume
5.83 million shares
Today's Range
$114.13
$117.60
50-Day Range
$102.50
$114.54
52-Week Range
$72.43
$119.96
Dividend Yield
2.79%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$50.37 +0.24 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$49.93 -0.44 (-0.87%)
As of 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple positive ratings from analysts, including a "strong-buy" rating, indicating strong confidence in the company's future performance.
  • The current stock price is around $50, which is below the average target price of $61.50 set by analysts, suggesting potential for price appreciation.
  • Sanofi recently reported earnings that exceeded analysts' expectations, showcasing its ability to generate revenue and manage costs effectively.

Cons of Sanofi

  • Sanofi's revenue has shown a decline of about 11% year-over-year, which may raise concerns about its growth prospects.
  • The stock has experienced volatility, with a 52-week high of $60.12 and a low of $45.80, indicating potential instability in its market performance.
  • Despite positive earnings, the company reported a significant drop in earnings per share compared to the previous year, which could signal underlying challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$122.94 billion
P/E Ratio
17.99
Consensus Rating
Buy
Consensus Price Target
$61.50 (+22.1% Upside)
Volume
1.47 million shares
Average Volume
1.72 million shares
Today's Range
$49.65
$50.37
50-Day Range
$47.62
$52.90
52-Week Range
$45.80
$60.12
Dividend Yield
3.19%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$469.65 -2.62 (-0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$469.68 +0.03 (+0.01%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $477, which reflects a recent increase of 1.5%, indicating positive market sentiment.
  • Vertex Pharmaceuticals Incorporated has a strong market capitalization of approximately $122.50 billion, suggesting robust financial health and stability.
  • The company has a consensus rating of "Moderate Buy" from analysts, with a significant average price target of $512.30, indicating potential for price appreciation.

Cons of Vertex Pharmaceuticals

  • The company reported earnings per share of $4.06, which missed analysts' expectations, indicating potential challenges in meeting financial targets.
  • Vertex Pharmaceuticals Incorporated has a negative net margin of 8.91%, suggesting that the company is currently operating at a loss, which could be a red flag for investors.
  • The stock has a price-to-earnings ratio of -121.67, indicating that the company is not currently generating profits relative to its stock price, which may deter some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$121.28 billion
P/E Ratio
-119.81
Consensus Rating
Moderate Buy
Consensus Price Target
$512.30 (+9.1% Upside)
Volume
1.18 million shares
Average Volume
1.08 million shares
Today's Range
$465.84
$472.71
50-Day Range
$434.03
$479.53
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

20. Medtronic NYSE:MDT

$92.91 +0.59 (+0.64%)
Closing price 03:59 PM Eastern
Extended Trading
$92.52 -0.38 (-0.41%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $92, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Medtronic plc recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $1.62, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $118.45 billion, reflecting its stability and presence in the healthcare market.

Cons of Medtronic

  • The stock has a relatively high price-to-earnings (P/E) ratio of 25.51, which may indicate that it is overvalued compared to its earnings potential.
  • Despite recent earnings growth, the company's revenue growth rate of 3.9% year-over-year may not be sufficient to meet the high expectations set by investors.
  • Medtronic plc has a debt-to-equity ratio of 0.53, which, while manageable, indicates that the company is using some leverage that could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.40 billion
P/E Ratio
25.66
Consensus Rating
Moderate Buy
Consensus Price Target
$98.19 (+5.7% Upside)
Volume
5.26 million shares
Average Volume
7.08 million shares
Today's Range
$91.93
$93.10
50-Day Range
$80.70
$92.35
52-Week Range
$78.32
$96.25
Dividend Yield
3.08%
Bristol Myers Squibb stock logo

21. Bristol Myers Squibb NYSE:BMY

$48.44 -0.51 (-1.03%)
Closing price 03:59 PM Eastern
Extended Trading
$48.40 -0.03 (-0.07%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $58.53, which reflects a stable valuation in the biopharmaceutical sector.
  • Bristol-Myers Squibb has a diverse portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • The company has received positive ratings from several analysts, with a consensus target price indicating potential for appreciation in stock value.

Cons of Bristol Myers Squibb

  • Despite a solid product lineup, the company faces intense competition in the biopharmaceutical industry, which could impact market share and pricing power.
  • Recent analyst reports indicate a mix of ratings, with some analysts maintaining a "hold" rating, suggesting caution among investors.
  • Corporate insiders own only a small percentage of the company's stock, which may indicate a lack of confidence in the company's future performance from those closest to it.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$99.60 billion
P/E Ratio
18.14
Consensus Rating
Hold
Consensus Price Target
$58.53 (+20.8% Upside)
Volume
11.84 million shares
Average Volume
12.21 million shares
Today's Range
$47.29
$49.24
50-Day Range
$46.34
$50.68
52-Week Range
$44.00
$63.33
Dividend Yield
5.07%
McKesson stock logo

22. McKesson NYSE:MCK

$711.80 +1.61 (+0.23%)
Closing price 03:59 PM Eastern
Extended Trading
$716.40 +4.60 (+0.65%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. has received multiple upgrades from analysts, with target prices reaching as high as $805, indicating strong growth potential.
  • The current stock price is around $711.80, reflecting a solid performance in the market and investor confidence.
  • Institutional investors hold a significant portion of McKesson Co.'s stock, with over 85% owned by such entities, suggesting strong institutional support.

Cons of McKesson

  • Despite positive ratings, some analysts have downgraded their outlook, indicating potential volatility in stock performance.
  • Recent fluctuations in stock price may suggest uncertainty in the market, which could deter risk-averse investors.
  • McKesson Co. faces competition in the healthcare sector, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.85 billion
P/E Ratio
27.56
Consensus Rating
Moderate Buy
Consensus Price Target
$710.17 (-0.2% Downside)
Volume
431,229 shares
Average Volume
586,523 shares
Today's Range
$709.96
$716.90
50-Day Range
$705.18
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.40%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$334.26 -7.22 (-2.11%)
Closing price 03:59 PM Eastern
Extended Trading
$334.38 +0.13 (+0.04%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The company recently reported earnings per share (EPS) of $6.84, significantly exceeding analysts' expectations, indicating strong financial performance.
  • HCA Healthcare, Inc. has shown a robust year-over-year revenue growth of 6.4%, suggesting a positive trend in its business operations.
  • The current stock price is around $369, reflecting a solid valuation in the healthcare sector.

Cons of HCA Healthcare

  • Insider selling has been observed, with the COO recently selling a significant number of shares, which may raise concerns about the company's future prospects.
  • Analysts have mixed ratings on the stock, with some downgrading their recommendations, indicating uncertainty in market sentiment.
  • The stock has experienced fluctuations, and recent downgrades from firms like Baird R W suggest potential volatility ahead.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$82.15 billion
P/E Ratio
14.86
Consensus Rating
Moderate Buy
Consensus Price Target
$399.46 (+19.5% Upside)
Volume
3.18 million shares
Average Volume
1.33 million shares
Today's Range
$330.00
$345.00
50-Day Range
$340.75
$389.81
52-Week Range
$289.98
$417.14
Dividend Yield
0.84%
Cigna Group stock logo

24. Cigna Group NYSE:CI

$296.36 +2.43 (+0.83%)
Closing price 03:59 PM Eastern
Extended Trading
$294.55 -1.81 (-0.61%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $296, which may present a buying opportunity for investors looking for value in the health services sector.
  • The company reported a significant revenue increase of 14.4% year-over-year, indicating strong growth potential and effective business strategies.
  • Analysts have a consensus rating of "Buy" for The Cigna Group, with a target price averaging around $380.39, suggesting potential upside for investors.

Cons of Cigna Group

  • Despite strong earnings, the stock has experienced volatility, which may pose risks for investors seeking stability.
  • The company's debt-to-equity ratio of 0.65 indicates a moderate level of debt, which could impact financial flexibility in challenging market conditions.
  • With a market capitalization of $79.20 billion, The Cigna Group may face challenges in maintaining growth rates as it scales, especially in a competitive industry.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.52 billion
P/E Ratio
16.41
Consensus Rating
Buy
Consensus Price Target
$380.39 (+28.4% Upside)
Volume
1.33 million shares
Average Volume
1.72 million shares
Today's Range
$294.00
$298.85
50-Day Range
$293.67
$334.71
52-Week Range
$262.03
$370.83
Dividend Yield
2.05%
GSK stock logo

25. GSK NYSE:GSK

$37.95 -0.28 (-0.72%)
Closing price 03:59 PM Eastern
Extended Trading
$37.88 -0.07 (-0.18%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $38.26, which may present a buying opportunity for investors looking for value.
  • GSK plc recently reported strong earnings, with earnings per share exceeding expectations, indicating robust financial performance.
  • The company has increased its quarterly dividend to $0.4216, reflecting a commitment to returning value to shareholders and a healthy dividend yield of approximately 4.41%.

Cons of GSK

  • One research analyst has rated GSK plc with a "sell" rating, which may indicate potential concerns about the stock's future performance.
  • GSK plc has a relatively high debt-to-equity ratio of 1.21, suggesting that the company relies significantly on debt financing, which can be risky in volatile markets.
  • The stock has experienced fluctuations, with a 12-month high of $44.67 and a low of $31.72, indicating potential volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.27 billion
P/E Ratio
19.56
Consensus Rating
Hold
Consensus Price Target
$37.38 (-1.5% Downside)
Volume
4.01 million shares
Average Volume
5.82 million shares
Today's Range
$37.51
$37.97
50-Day Range
$36.21
$42.50
52-Week Range
$31.72
$44.67
Dividend Yield
4.47%
CVS Health stock logo

26. CVS Health NYSE:CVS

$60.67 +1.92 (+3.27%)
Closing price 03:59 PM Eastern
Extended Trading
$60.68 +0.02 (+0.02%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported strong earnings, with an EPS of $2.25, significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue growth of 7.0%, reflecting its ability to expand and capture market share in the health solutions sector.
  • CVS Health Co. has declared a quarterly dividend of $0.665 per share, which translates to an annualized dividend of $2.66, providing a yield of approximately 4.41% for investors seeking income.

Cons of CVS Health

  • Despite recent growth, CVS Health Co. has a relatively low net margin of 1.39%, which may raise concerns about profitability compared to competitors.
  • The stock price has shown volatility, and while it is currently around $63.70, fluctuations could pose risks for short-term investors.
  • With a payout ratio of 63.48%, a significant portion of earnings is distributed as dividends, which may limit funds available for reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$74.32 billion
P/E Ratio
14.48
Consensus Rating
Moderate Buy
Consensus Price Target
$75.13 (+23.8% Upside)
Volume
10.88 million shares
Average Volume
6.44 million shares
Today's Range
$59.44
$61.17
50-Day Range
$58.82
$69.56
52-Week Range
$43.56
$72.51
Dividend Yield
4.53%
Zoetis stock logo

27. Zoetis NYSE:ZTS

$151.92 -0.90 (-0.59%)
Closing price 03:59 PM Eastern
Extended Trading
$151.96 +0.04 (+0.03%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $156, which reflects a solid position in the market and potential for growth.
  • Recent institutional investments indicate strong confidence in Zoetis Inc., with 92.80% of the stock owned by institutional investors and hedge funds.
  • Zoetis Inc. has shown significant growth in holdings by major investors, such as Edgestream Partners L.P., which increased its stake by 466.4% recently, suggesting strong future prospects.

Cons of Zoetis

  • Despite the positive outlook, the stock has experienced fluctuations, with a fifty-two week high of $200.33 and a low of $139.70, indicating volatility.
  • Some analysts have downgraded their ratings, with Stifel Nicolaus lowering Zoetis from a "buy" to a "hold," which may signal caution among investors.
  • Insider selling, such as the recent sale of 652 shares by an executive vice president, could raise concerns about the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$68.04 billion
P/E Ratio
27.28
Consensus Rating
Moderate Buy
Consensus Price Target
$204.63 (+34.7% Upside)
Volume
3.33 million shares
Average Volume
2.97 million shares
Today's Range
$151.23
$153.37
50-Day Range
$147.31
$170.40
52-Week Range
$139.70
$200.33
Dividend Yield
1.31%
Elevance Health stock logo

28. Elevance Health NYSE:ELV

$289.11 +8.68 (+3.10%)
Closing price 03:59 PM Eastern
Extended Trading
$289.87 +0.76 (+0.26%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$63.15 billion
P/E Ratio
12.30
Consensus Rating
Moderate Buy
Consensus Price Target
$418.19 (+44.6% Upside)
Volume
4.81 million shares
Average Volume
2.86 million shares
Today's Range
$283.00
$294.32
50-Day Range
$276.32
$412.49
52-Week Range
$274.40
$567.26
Dividend Yield
2.44%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$563.10 -1.54 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$562.00 -1.10 (-0.20%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $572, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The company recently declared a quarterly dividend of $0.88 per share, reflecting a commitment to returning value to shareholders, with an annualized yield of approximately 0.61%.

Cons of Regeneron Pharmaceuticals

  • The company recently missed earnings expectations, reporting $8.22 per share against a consensus estimate of $8.83, which may raise concerns about its financial performance.
  • Regeneron Pharmaceuticals, Inc. has seen a revenue decline of 3.7% compared to the same quarter last year, indicating potential challenges in maintaining sales growth.
  • Some analysts have downgraded their price targets for the stock, with recent adjustments suggesting a more cautious outlook on its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.96 billion
P/E Ratio
14.34
Consensus Rating
Moderate Buy
Consensus Price Target
$828.86 (+47.2% Upside)
Volume
755,785 shares
Average Volume
906,903 shares
Today's Range
$555.50
$567.21
50-Day Range
$483.07
$614.79
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.62%
Cencora stock logo

30. Cencora NYSE:COR

$290.17 -0.28 (-0.10%)
Closing price 03:59 PM Eastern
Extended Trading
$289.00 -1.17 (-0.40%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $290, which reflects a strong performance in the market.
  • Analysts have a consensus rating of "Moderate Buy" for Cencora, Inc., indicating positive sentiment among market experts.
  • Recent target price increases from various research firms suggest confidence in the company's growth potential, with some estimates reaching as high as $350.

Cons of Cencora

  • The stock has experienced fluctuations, with a twelve-month high of $309.35 and a low of $218.65, indicating potential volatility.
  • Despite positive analyst ratings, the market can be unpredictable, and external factors may impact stock performance.
  • The company's payout ratio is 25.52%, which, while sustainable, may limit future dividend increases.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.30 billion
P/E Ratio
33.66
Consensus Rating
Moderate Buy
Consensus Price Target
$309.83 (+6.8% Upside)
Volume
785,267 shares
Average Volume
1.07 million shares
Today's Range
$289.40
$293.14
50-Day Range
$283.94
$302.43
52-Week Range
$218.65
$309.35
Dividend Yield
0.76%
Becton, Dickinson and Company stock logo

31. Becton, Dickinson and Company NYSE:BDX

$185.52 +1.89 (+1.03%)
Closing price 03:59 PM Eastern
Extended Trading
$185.78 +0.27 (+0.14%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $181.50, showing a recent increase of 3.5%, which may indicate positive market sentiment.
  • Becton, Dickinson and Company has a strong market capitalization of approximately $52 billion, suggesting stability and a solid position in the medical instruments sector.
  • The company reported earnings per share (EPS) of $3.35, exceeding analyst expectations, which reflects strong financial performance and potential for growth.

Cons of Becton, Dickinson and Company

  • Analysts have recently downgraded the stock from "buy" to "neutral," which may indicate a lack of confidence in short-term growth.
  • The company has faced revenue challenges, reporting $5.27 billion for the quarter, which was below analyst estimates, suggesting potential operational difficulties.
  • With a price-to-earnings (P/E) ratio of 34.64, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$52.63 billion
P/E Ratio
35.40
Consensus Rating
Hold
Consensus Price Target
$219.22 (+18.2% Upside)
Volume
1.88 million shares
Average Volume
2.93 million shares
Today's Range
$183.42
$185.92
50-Day Range
$168.54
$183.62
52-Week Range
$163.33
$251.99
Dividend Yield
2.27%
Veeva Systems stock logo

32. Veeva Systems NYSE:VEEV

$290.73 -0.52 (-0.18%)
Closing price 03:59 PM Eastern
Extended Trading
$295.00 +4.26 (+1.47%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $282, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Veeva Systems Inc. reported strong quarterly earnings, exceeding analysts' expectations, which demonstrates robust financial performance and growth potential.
  • The company has shown a significant year-over-year revenue increase, suggesting a solid demand for its cloud-based software solutions in the life sciences sector.

Cons of Veeva Systems

  • The stock has experienced fluctuations, with a recent high of $291.69 and a low of $177.41 over the past year, indicating potential volatility that could affect investment returns.
  • Insider selling activity has been noted, with recent transactions indicating a decrease in positions by key executives, which may raise concerns about their confidence in the company's future performance.
  • The company's P/E ratio is relatively high at 59.75, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.59 billion
P/E Ratio
61.60
Consensus Rating
Moderate Buy
Consensus Price Target
$274.17 (-5.7% Downside)
Volume
1.21 million shares
Average Volume
1.23 million shares
Today's Range
$288.37
$294.00
50-Day Range
$233.41
$291.26
52-Week Range
$177.41
$294.00
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

33. Takeda Pharmaceutical NYSE:TAK

$14.46 -0.20 (-1.33%)
Closing price 03:59 PM Eastern
Extended Trading
$14.48 +0.01 (+0.08%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.67, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Recent institutional investments, such as Vontobel Holding Ltd. acquiring a stake valued at approximately $262,000, indicate growing confidence in the company's future performance.
  • Takeda Pharmaceutical Company Limited has shown resilience with a market capitalization of $46.68 billion, suggesting stability and potential for growth in the competitive pharmaceutical market.

Cons of Takeda Pharmaceutical

  • The company reported earnings per share of $0.16, which fell short of the consensus estimate of $0.24, raising concerns about its profitability and ability to meet market expectations.
  • Takeda Pharmaceutical Company Limited has a net margin of only 2.36%, indicating that its profitability may be under pressure, which could affect future earnings growth.
  • Despite recent investments, only 9.17% of the stock is owned by institutional investors and hedge funds, suggesting a lack of widespread institutional confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.65 billion
P/E Ratio
65.75
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
6.38 million shares
Average Volume
2.94 million shares
Today's Range
$14.35
$14.60
50-Day Range
$14.11
$15.55
52-Week Range
$12.80
$15.53
Dividend Yield
3.76%
Alcon stock logo

34. Alcon NYSE:ALC

$91.79 -0.11 (-0.12%)
Closing price 03:59 PM Eastern
Extended Trading
$91.86 +0.06 (+0.07%)
As of 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that may attract investors.
  • The company has a significant institutional ownership percentage, suggesting confidence from large investors in its future prospects.

Cons of Alcon

  • The average daily volume has decreased, which may indicate reduced investor interest and liquidity in the stock.
  • There has been a notable increase in shares shorted in the previous month, which could signal bearish sentiment among some investors.
  • The month-to-month change percentage in shares shorted shows a decline, which might suggest uncertainty about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.33 billion
P/E Ratio
40.80
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+15.6% Upside)
Volume
954,804 shares
Average Volume
1.52 million shares
Today's Range
$90.71
$91.86
50-Day Range
$84.77
$92.25
52-Week Range
$80.48
$101.10
Dividend Yield
N/A
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$79.92 +4.12 (+5.43%)
Closing price 03:59 PM Eastern
Extended Trading
$79.60 -0.32 (-0.40%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $76, reflecting a stable performance in the market.
  • Recent earnings reports showed a positive trend, with earnings per share exceeding analyst expectations, indicating strong financial health.
  • The company has a robust market capitalization of approximately $44.87 billion, suggesting a solid position in the industry.

Cons of Edwards Lifesciences

  • Despite positive earnings, the stock has seen fluctuations, with a 12-month high of $88.50 and a low of $58.93, indicating potential volatility.
  • Insider selling activity has been noted, with significant shares sold by executives, which may raise concerns about their confidence in the company's future.
  • The company has a relatively high P/E ratio, which could suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.46 billion
P/E Ratio
11.50
Consensus Rating
Moderate Buy
Consensus Price Target
$85.00 (+6.4% Upside)
Volume
15.66 million shares
Average Volume
3.81 million shares
Today's Range
$77.52
$83.00
50-Day Range
$73.31
$78.79
52-Week Range
$59.41
$83.00
Dividend Yield
N/A
Haleon stock logo

36. Haleon NYSE:HLN

$9.86 +0.02 (+0.15%)
Closing price 03:59 PM Eastern
Extended Trading
$9.85 -0.01 (-0.11%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $10.39, which may present a buying opportunity for investors looking for value.
  • Haleon plc has received multiple upgrades from analysts, including a recent upgrade to "outperform" with a price target of $13.40, indicating positive market sentiment.
  • The company has a solid market capitalization of approximately $46.70 billion, suggesting stability and potential for growth.

Cons of Haleon

  • The stock has experienced a slight decline of about 0.3% recently, which may indicate short-term volatility.
  • Haleon plc has a relatively high P/E ratio of 26.63, which could suggest that the stock is overvalued compared to its earnings.
  • The company has a quick ratio of 0.78, indicating that it may have some challenges in meeting short-term liabilities without selling inventory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.25 billion
P/E Ratio
25.26
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+24.9% Upside)
Volume
9.88 million shares
Average Volume
12.17 million shares
Today's Range
$9.78
$9.88
50-Day Range
$9.52
$11.42
52-Week Range
$8.86
$11.42
Dividend Yield
2.53%
IDEXX Laboratories stock logo

37. IDEXX Laboratories NASDAQ:IDXX

$565.19 +15.22 (+2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$565.29 +0.10 (+0.02%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $563, reflecting a recent increase of 2.4%, which may indicate positive market sentiment towards the company.
  • IDEXX Laboratories, Inc. reported a quarterly earnings per share (EPS) of $2.96, surpassing analyst expectations, which suggests strong financial performance and potential for future growth.
  • The company achieved a revenue of approximately $998 million in the latest quarter, showing a year-over-year growth of 3.6%, indicating a stable demand for its products.

Cons of IDEXX Laboratories

  • The stock has a high price-to-earnings (P/E) ratio of 52.06, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent insider selling, including a director selling 1,260 shares, could indicate a lack of confidence in the company's short-term performance, which may concern potential investors.
  • The company operates in a competitive market, and any changes in market dynamics or regulatory environments could adversely affect its performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.23 billion
P/E Ratio
52.24
Consensus Rating
Moderate Buy
Consensus Price Target
$557.88 (-1.3% Downside)
Volume
1.07 million shares
Average Volume
425,413 shares
Today's Range
$548.78
$568.47
50-Day Range
$500.87
$549.97
52-Week Range
$356.14
$568.47
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

38. Alnylam Pharmaceuticals NASDAQ:ALNY

$328.81 +0.81 (+0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$328.84 +0.03 (+0.01%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $328.81, reflecting a recent increase, which may indicate positive market sentiment towards the company's performance.
  • Alnylam Pharmaceuticals, Inc. reported a revenue increase of over 20% compared to the same quarter last year, showcasing strong growth potential in its business operations.
  • Institutional investors and hedge funds own approximately 92.97% of the company's stock, suggesting strong confidence from major financial players in the company's future prospects.

Cons of Alnylam Pharmaceuticals

  • The company has a negative price-to-earnings (P/E) ratio, which indicates that it is currently not profitable, raising concerns about its ability to generate earnings in the near future.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio of 8.88, suggesting that it relies heavily on debt financing, which could pose risks if the company faces financial difficulties.
  • Recent insider selling, including a significant transaction by the CEO, may raise red flags for potential investors regarding the company's future outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.77 billion
P/E Ratio
-157.33
Consensus Rating
Moderate Buy
Consensus Price Target
$347.75 (+5.8% Upside)
Volume
666,674 shares
Average Volume
911,887 shares
Today's Range
$324.55
$331.50
50-Day Range
$285.31
$331.94
52-Week Range
$205.87
$333.70
Dividend Yield
N/A
ResMed stock logo

39. ResMed NYSE:RMD

$275.29 +1.79 (+0.65%)
Closing price 03:59 PM Eastern
Extended Trading
$275.20 -0.09 (-0.03%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The company reported strong quarterly earnings, with earnings per share exceeding expectations, indicating robust financial health and effective management.
  • ResMed Inc. has shown a year-over-year revenue growth of nearly 8%, suggesting a positive trend in demand for its medical devices and software solutions.
  • The current stock price is around $242, reflecting investor confidence and a stable market position in the healthcare sector.

Cons of ResMed

  • Insider selling activity has been noted, with significant shares sold by directors, which may raise concerns about their confidence in the company's future performance.
  • Despite revenue growth, the competitive landscape in the medical device industry is intense, which could impact future profitability and market share.
  • Institutional ownership is relatively high, which can lead to volatility if large investors decide to sell their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.10 billion
P/E Ratio
30.90
Consensus Rating
Moderate Buy
Consensus Price Target
$263.00 (-4.5% Downside)
Volume
1.06 million shares
Average Volume
824,604 shares
Today's Range
$271.53
$275.80
50-Day Range
$243.03
$273.43
52-Week Range
$196.43
$275.80
Dividend Yield
0.78%
Cardinal Health stock logo

40. Cardinal Health NYSE:CAH

$157.10 -1.19 (-0.75%)
Closing price 03:59 PM Eastern
Extended Trading
$157.63 +0.53 (+0.34%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $159.45, which reflects a strong performance in the market and may indicate potential for growth.
  • Recent upgrades from multiple analysts, including a price target increase to $190.00 by Morgan Stanley, suggest positive sentiment and confidence in the company's future performance.
  • Cardinal Health, Inc. has consistently reported earnings that beat analysts' expectations, indicating strong operational performance and effective management.

Cons of Cardinal Health

  • The company has a negative return on equity, which may raise concerns about its ability to generate profit from shareholders' investments.
  • Despite recent revenue growth, the company reported a net margin of only 0.70%, indicating potential challenges in profitability.
  • Analysts have noted that the revenue for the latest quarter fell short of expectations, which could signal underlying issues in sales performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.78 billion
P/E Ratio
24.51
Consensus Rating
Moderate Buy
Consensus Price Target
$158.07 (+0.6% Upside)
Volume
1.21 million shares
Average Volume
1.86 million shares
Today's Range
$157.04
$159.25
50-Day Range
$152.41
$167.92
52-Week Range
$96.05
$168.44
Dividend Yield
1.29%
argenex stock logo

41. argenex NASDAQ:ARGX

$591.99 +0.25 (+0.04%)
Closing price 04:00 PM Eastern
Extended Trading
$591.96 -0.03 (-0.01%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Market Capitalization
$36.21 billion
P/E Ratio
36.52
Consensus Rating
Buy
Consensus Price Target
$728.06 (+23.0% Upside)
Volume
493,117 shares
Average Volume
430,326 shares
Today's Range
$587.37
$594.45
50-Day Range
$537.92
$591.74
52-Week Range
$473.67
$678.21
Dividend Yield
N/A
GE HealthCare Technologies stock logo

42. GE HealthCare Technologies NASDAQ:GEHC

$77.61 +0.84 (+1.09%)
Closing price 04:00 PM Eastern
Extended Trading
$77.81 +0.20 (+0.26%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Market Capitalization
$35.15 billion
P/E Ratio
16.69
Consensus Rating
Moderate Buy
Consensus Price Target
$88.55 (+14.1% Upside)
Volume
3.13 million shares
Average Volume
3.28 million shares
Today's Range
$75.97
$77.83
50-Day Range
$69.16
$77.61
52-Week Range
$57.65
$94.80
Dividend Yield
0.18%
Agilent Technologies stock logo

43. Agilent Technologies NYSE:A

$120.17 -0.18 (-0.15%)
Closing price 03:59 PM Eastern
Extended Trading
$120.23 +0.06 (+0.05%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The company reported earnings per share of $1.31 for the latest quarter, exceeding analyst expectations, which indicates strong financial performance.
  • Agilent Technologies, Inc. has shown a revenue increase of 6.0% compared to the same quarter last year, suggesting growth in its business operations.
  • The current stock price is around $119.89, reflecting a recent increase, which may indicate positive market sentiment.

Cons of Agilent Technologies

  • Analysts have mixed ratings on the stock, with several price targets being reduced, indicating potential uncertainty in future performance.
  • Insider selling activity, such as the CEO selling shares, may raise concerns about the company's future prospects and insider confidence.
  • The stock has experienced volatility, with a 12-month high of $153.84 and a low of $96.43, suggesting potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.19 billion
P/E Ratio
29.67
Consensus Rating
Moderate Buy
Consensus Price Target
$139.77 (+16.3% Upside)
Volume
1.97 million shares
Average Volume
1.76 million shares
Today's Range
$119.02
$121.01
50-Day Range
$108.61
$124.18
52-Week Range
$96.43
$153.84
Dividend Yield
0.82%
IQVIA stock logo

44. IQVIA NYSE:IQV

$199.17 -1.65 (-0.82%)
Closing price 03:59 PM Eastern
Extended Trading
$198.85 -0.32 (-0.16%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Market Capitalization
$34.14 billion
P/E Ratio
28.82
Consensus Rating
Moderate Buy
Consensus Price Target
$228.62 (+14.8% Upside)
Volume
2.14 million shares
Average Volume
2.28 million shares
Today's Range
$195.32
$201.04
50-Day Range
$136.96
$201.06
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
DexCom stock logo

45. DexCom NASDAQ:DXCM

$88.99 +2.25 (+2.59%)
Closing price 04:00 PM Eastern
Extended Trading
$88.70 -0.30 (-0.33%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $83.62, which may present a buying opportunity for investors looking for growth in the medical device sector.
  • Recent analyst ratings show a consensus of "Moderate Buy," indicating positive sentiment among financial experts regarding the stock's potential for appreciation.
  • DexCom, Inc. reported a revenue increase of 12.5% compared to the same quarter last year, showcasing strong business growth and demand for its continuous glucose monitoring systems.

Cons of DexCom

  • The stock has a high price-to-earnings ratio of 62.49, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent insider selling, with directors offloading shares, could signal a lack of confidence in the company's short-term performance.
  • Analysts have varied opinions, with some downgrading their ratings, which may create uncertainty about the stock's future trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.01 billion
P/E Ratio
66.41
Consensus Rating
Moderate Buy
Consensus Price Target
$99.60 (+11.9% Upside)
Volume
3.07 million shares
Average Volume
2.73 million shares
Today's Range
$86.69
$89.07
50-Day Range
$79.84
$87.57
52-Week Range
$57.52
$93.25
Dividend Yield
N/A
BeOne Medicines stock logo

46. BeOne Medicines NASDAQ:ONC

$291.47 -4.99 (-1.68%)
As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$32.49 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$327.56 (+12.4% Upside)
Volume
171,226 shares
Average Volume
369,628 shares
Today's Range
$287.00
$293.17
50-Day Range
$228.38
$296.46
52-Week Range
$155.75
$300.00
Dividend Yield
N/A
Humana stock logo

47. Humana NYSE:HUM

$238.22 +9.01 (+3.93%)
Closing price 03:59 PM Eastern
Extended Trading
$238.70 +0.48 (+0.20%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Market Capitalization
$27.66 billion
P/E Ratio
16.85
Consensus Rating
Hold
Consensus Price Target
$282.43 (+18.6% Upside)
Volume
1.57 million shares
Average Volume
1.51 million shares
Today's Range
$231.10
$239.82
50-Day Range
$220.08
$255.23
52-Week Range
$206.87
$406.09
Dividend Yield
1.54%
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$115.31 +0.74 (+0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$114.91 -0.40 (-0.35%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • The current stock price is around $112.89, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $131.49.
  • BioNTech SE has a strong financial position, evidenced by a quick ratio of 10.02 and a current ratio of 10.18, indicating excellent liquidity and the ability to cover short-term obligations.
  • The company has a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing, which can reduce financial risk for investors.

Cons of BioNTech

  • The stock has a negative P/E ratio, which can indicate that the company is currently unprofitable, raising concerns about its ability to generate earnings in the near term.
  • Recent trading volumes have been below average, which may suggest a lack of investor interest or confidence in the stock at its current price levels.
  • Despite a strong market cap of approximately $27.14 billion, the volatility indicated by a beta of 1.29 suggests that the stock may experience larger price swings compared to the overall market, which can be risky for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.54 billion
P/E Ratio
-33.91
Consensus Rating
Moderate Buy
Consensus Price Target
$136.58 (+18.4% Upside)
Volume
392,122 shares
Average Volume
579,799 shares
Today's Range
$113.54
$115.54
50-Day Range
$95.71
$115.64
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$1,263.97 +3.22 (+0.26%)
Closing price 03:59 PM Eastern
Extended Trading
$1,263.49 -0.47 (-0.04%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,256, reflecting a strong market position and investor confidence in the company's growth potential.
  • Mettler-Toledo International Inc. has recently reported earnings that exceeded analysts' expectations, indicating robust financial health and operational efficiency.
  • Institutional investors hold a significant majority of the stock, suggesting strong confidence from large financial entities in the company's future performance.

Cons of Mettler-Toledo International

  • The stock has experienced fluctuations, with a recent trading volume lower than its average, which may indicate reduced investor interest or market volatility.
  • Despite recent earnings growth, the company's revenue has shown a decline compared to the previous year, raising concerns about long-term sustainability.
  • High price-to-earnings and price-to-earnings-growth ratios suggest that the stock may be overvalued, which could lead to a correction in the future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.20 billion
P/E Ratio
31.52
Consensus Rating
Hold
Consensus Price Target
$1,280.90 (+1.3% Upside)
Volume
155,612 shares
Average Volume
136,780 shares
Today's Range
$1,246.16
$1,268.56
50-Day Range
$1,115.43
$1,262.53
52-Week Range
$946.69
$1,546.93
Dividend Yield
N/A
Koninklijke Philips stock logo

50. Koninklijke Philips NYSE:PHG

$26.16 +0.32 (+1.22%)
Closing price 03:59 PM Eastern
Extended Trading
$26.16 0.00 (0.00%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $24, showing a slight increase recently, which may indicate positive market sentiment.
  • Recent earnings reports have exceeded analysts' expectations, suggesting strong operational performance and potential for future growth.
  • Analysts have a consensus rating of "Moderate Buy," indicating a generally favorable outlook for the stock among financial experts.

Cons of Koninklijke Philips

  • The stock has shown volatility, with a 12-month high of $31.57 and a low of $20.61, indicating potential risks associated with price fluctuations.
  • Recent revenue reports showed a year-over-year decline, which could signal challenges in maintaining growth momentum.
  • The company's price-to-earnings (P/E) ratio is relatively high, suggesting that the stock may be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.88 billion
P/E Ratio
60.83
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
918,989 shares
Average Volume
904,553 shares
Today's Range
$25.66
$26.18
50-Day Range
$22.08
$25.84
52-Week Range
$21.48
$32.91
Dividend Yield
3.18%